伦敦生物技术初创公司Baseimmune近日宣布成功完成1130万美元（约900万英镑）的A轮融资，这标志着其利用人工智能技术设计和开发疫苗的创新项目迈出了重要一步。此轮融资得到了众多知名投资者的超额认购，其中包括MSD Global Health Innovation Fund、IQ Capital，以及早期投资者Hoxton Ventures、Creator Fund、Beast Ventures和Maki.vc。
Baseimmune公司致力于利用先进的机器学习平台，简化疫苗设计过程，以期加速疫苗的研发并提高其效力。这笔资金的注入将为Baseimmune提供必要的资源，推动其技术平台的进一步开发，并可能加速潜在疫苗项目的临床试验进程。
MSD Global Health Innovation Fund等投资者的参与，反映出全球对利用人工智能解决公共卫生挑战的日益增长的兴趣。Baseimmune的创新方法有望重塑疫苗研发领域，提高应对新出现和已知传染病的能力。
Baseimmune的首席执行官表示，这笔资金将用于扩大团队规模，提升技术能力，并与业界合作伙伴建立更紧密的联系，以共同应对全球健康威胁。他表示：“我们非常荣幸能得到这些顶级投资机构的支持，这不仅是对我们现有工作的认可，也是对我们未来潜力的肯定。我们将继续致力于利用AI技术，为全球公共卫生带来革命性的改变。”
Baseimmune的A轮融资成功，不仅为公司自身发展注入了活力，也为整个生物技术行业展示了人工智能在医疗健康领域的广阔应用前景。
英语如下：
**News Title:** “London Biotech Company Baseimmune Secures $11.3M Series A Funding to Accelerate AI-Powered Vaccine Design Innovation”
**Keywords:** Baseimmune, Vaccine Development, AI Funding
**News Content:** London-based biotech startup Baseimmune recently announced the successful completion of a $11.3 million (approximately £9 million) Series A funding round, marking a significant step forward in its innovative project to design and develop vaccines using artificial intelligence technology. The round was oversubscribed by a number of prominent investors, including MSD Global Health Innovation Fund, IQ Capital, as well as early investors Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc.
Baseimmune focuses on leveraging advanced machine learning platforms to streamline the vaccine design process, aiming to accelerate vaccine development and enhance their efficacy. The influx of funds will provide Baseimmune with the necessary resources to further develop its technology platform and potentially expedite the clinical trial process for prospective vaccine projects.
The involvement of investors like MSD Global Health Innovation Fund underscores the growing global interest in using artificial intelligence to address public health challenges. Baseimmune’s innovative approach has the potential to reshape the vaccine development landscape and enhance the response to emerging and known infectious diseases.
The CEO of Baseimmune stated that the funding will be utilized to expand the team, enhance technological capabilities, and forge closer collaborations with industry partners to tackle global health threats collectively. He remarked, “We are thrilled to have the backing of these leading investment firms, which not only validates our current work but also believes in our future potential. We remain committed to revolutionizing global public health through the application of AI technology.”
Baseimmune’s successful Series A fundraising not only energizes the company’s growth but also demonstrates the broad applicability of artificial intelligence in the healthcare sector for the broader biotech industry.
【来源】https://www.maginative.com/article/baseimmune-closes-11-3m-series-a-to-accelerate-ai-designed-vaccines/
Views: 1